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Abstract
Background: There is a potential for adverse cardiovascular effects in long-term breast cancer survivors following
adjuvant radiotherapy (RT). For this purpose, the deep inspiration breath-hold technique (DIBH) has been
introduced into clinical practice, to maximally reduce the radiation dose to the heart. However, there are a variety
of DIBH delivery techniques, patient positioning and visual patient feedback mechanisms. The aim of the present
study was to evaluate the application of radiotherapy in DIBH using the CatalystTM/SentinelTM system, with a special
emphasis on treatment planning and dosimetric plan comparison in free breathing (FB) and DIBH.
Patients and methods: A total of 13 patients with left-sided breast cancer following breast conserving surgery
were included in this prospective clinical trial. For treatment application the CatalystTM/SentinelTM system (C-RAD
AB, Uppsala, Sweden) was used and gating control was performed by an audio-visual patient feedback system.
CT and surface data were acquired in FB and DIBH and dual treatment plans were created using Pencil Beam and
Collapsed Cone Convolution. Dosimetric output parameters of organs at risk were compared using Wilcoxon
signed-rank test. Central lung distance (CLD) was retrieved from iViewTM portal images during treatment delivery.
Results: The system contains a laser surface scanner (SentinelTM) and an optical surface scanner (CatalystTM)
interconnected to the LINAC systems via a gating interface and allows for a continuous and touchless surface
scanning. Overall, 225 treatment fractions with audio-visual guidance were completed without any substantial
difficulties. Following initial patient training and treatment setup, radiotherapy in DIBH with the CatalystTM/
SentinelTM system was time-efficient and reliable. Following dual treatment planning for all patients, nine of 13
patients were treated in DIBH. In these patients, the reduction of the mean heart dose for DIBH compared to FB
was 52 % (2.73 to 1.31 Gy; p = 0.011). The maximum doses to the heart and LAD were reduced by 59 % (47.90 to
19.74 Gy; p = 0.008) and 75 % (38.55 to 9.66 Gy; p = 0.008), respectively. In six of the nine patients the heart
completely moved out of the treatment field by DIBH. The standard deviation of the CLD varied between 0.12 and
0.29 cm (mean: 0.16 cm).
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Conclusion: The CatalystTM/SentinelTM system enabled a fast and reliable application and surveillance of DIBH in
daily clinical routine. Furthermore, the present data show that using the DIBH technique during RT could
significantly reduce high dose areas and mean doses to the heart.
Trial registration: DRKS: DRKS00010929 registered on 5. August 2016.
Keywords: Surface scanner, Left-sided, Breast cancer, Cardiac toxicity, Deep inspiration breath-hold (DIBH), Audio-
visual guided, CatalystTM
Introduction
Whole breast radiotherapy after breast-conserving sur-
gery is a fundamental cornerstone in the treatment of
early breast cancer and has been shown to halve the risk
of local recurrence and reduce the annual breast cancer
death rate by about one sixth [1]. Furthermore, modern
systemic treatment regimens containing substances such
as anthracyclines or the antibody trastuzumab, have sig-
nificantly improved progression free survival and overall
survival in patients with early breast cancer [2, 3]. How-
ever, these substances have been reported to induce rele-
vant cardiotoxicity and pose a risk for development of
life-threatening congestive heart failure [4]. The combin-
ation of anthracyclines and/or trastuzumab with RT may
synergistically influence the risk for cardiac toxicity [5].
Recent data suggest, that even lower radiation doses to
the heart may play a relevant role for the development of
late cardiac toxicity after breast cancer treatment [6–8].
Radiation exposure of the heart can result in coronary ar-
tery disease, congestive heart failure, valvular heart dis-
ease, pericardial disease, conduction abnormalities and
sudden cardiac death [9]. However, neither the exact
pathogenesis, nor the responsible anatomical substruc-
tures of the heart influencing late cardiac toxicity, or the
precise dose–response relationship are well understood.
At present, different clinical approaches were developed
in order to decrease the radiation dose to the heart in
breast cancer treatment: Technologies like forward-
planned and inverse-planned IMRT (including Tangential
IMRT) and helical tomotherapy [10–13] have been shown
to reduce the high dose exposure of the heart but often at
the expense of significantly increasing low dose exposures.
Another approach is the application of respiratory-
gated and breath-hold RT, such as deep inspiration
breath-hold (DIBH) [14–19], which probably allows for
a real dose reduction without any increases in low dose
areas. Currently, several vendor specific systems are in
use: for example the Active Breathing Control (ABC) de-
vice designed at William Beaumont Hospital, Michigan
[20]; the Varian Real-time Position Management system
(RPMTM) (Varian Medical Systems, Palo Alto, CA, USA
[21]), or the AlignRT system of Vision RT Ltd, London,
UK, [22]. Another system is the Respiratory Gating
Laser System AZ-733 V of the manufacturer Anzai using
a contactless laser sensor (Anzai Medical Co., Ltd,
Tokyo, Japan), or the breast belt system [23]. In the
present study the CatalystTM/SentinelTM system of C-
RAD AB, Uppsala, Sweden was used. The system con-
sists of a laser-based surface scanner (SentinelTM) and
an optical-based surface scanner (CatalystTM) intercon-
nected to the LINAC systems via the ResponseTM gating
interface. The system allows for a continuous surface
scanning, LINAC triggering and includes an active
patient feedback system (audio-visual guidance). In con-
trast to other vendor specific systems (ABC, RPM), there
is no device or “box” that has to be positioned on the
patient.
The objective of the present study was to evaluate
treatment planning and dosimetric plan comparison in
free breathing (FB) and DIBH, and the application of
radiotherapy in DIBH using the CatalystTM/SentinelTM
system in left-sided breast cancer patients in clinical
daily routine.
Materials and methods
The prospective study was performed in accordance
with the Declaration of Helsinki and was approved by
the ethical committee of the LMU medical faculty
(22.10.2013, No. 496–12). Inclusion criteria were informed
consent, left-sided breast cancer, breast conserving surgery
and patient compliance (ability of breath-hold for 20 s). A
total of 13 left-sided breast cancer patients, with a mean
age of 46.9 years (range: 36–63 years) were included in the
study. The workflow is depicted in Fig. 1, showing our clin-
ical routine with the initial training phase one and two, the
acquisition of the two planning CTs using the SentinelTM
scanner, the dual treatment planning, the clinical decision
making and the setup/treatment with the audio-visual gat-
ing and the CatalystTM system in the treatment room.
Treatment planning
All patients received two planning CT scans, one in free
breathing (FB) and one in DIBH, each with a slice thick-
ness of 3 mm. The heart and the left anterior descending
artery (LAD) were delineated according to the CT-based
atlas by Feng et al. [24]. In order to reduce the inter-
observer variability, the same physician delineated all or-
gans at risk (OAR). Target volume delineation, treatment
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planning and dose concepts were made according to the
German interdisciplinary consensus- based guideline
(“S3 guideline on “Diagnosis, Therapy, and Follow-up of
Breast Cancer” [25]) and the practical guidelines of the
Breast Cancer Expert Panel of the German Society of
Radiation Oncology (DEGRO) [1] and applied for both,
FB and DIBH. The clinical target volume (CTV) in-
cluded all remaining ipsilateral breast tissue, including
the deep fascia but not the underlying muscle or over-
laying skin. The margin for the planning target volume
(PTV) was 0.5-1.0 cm covering the entire breast and tak-
ing into account adjustments on the medial and lateral
borders. The prescribed dose was 50.0 Gy (2.0 Gy/d).
Treatment planning was performed using the Oncentra
4.3 (Nucletron, Veenendaal, Netherlands) software. To en-
sure consistency, all treatment plans were made by the
same physicist. The algorithm used for dose calculation
was Collapsed Cone Convolution (CCC) with a 3 mm×
3 mm calculation grid. For dosimetric plan comparison all
plans were additionally recalculated in Pencil Beam Con-
volution (PBC).
The following parameters were derived from the
DVHs of the different treatment plans: the mean and
the maximum dose to the heart (Dmean, Dmax), and the
relative volume of the heart receiving at least 5, 10, 15,
20, 25, 35 and 45 Gy (V5–V45). The dosimetric param-
eter V25 of the heart was used as a cut-off value in order
to decide if a patient was treated using the DIBH
manoeuvre or not. Patients presenting with low cardiac
dose exposure (V25 of 0 % in FB) would most likely not
benefit from RT in DIBH. The dose to 2 % of the LAD
volume (D2%) was recorded as a robust estimator for the
maximum dose to the LAD and the D2% of the 10 mm
expanded LAD. Further parameters included: The PTV
Fig. 1 Schematic overview of the clinical workflow
Schönecker et al. Radiation Oncology  (2016) 11:143 Page 3 of 10
coverage described by the volume receiving 95 % of the
prescribed dose (V95%), the mean doses to right and left
lung, as well as the volume of the left lung receiving
more than 20 Gy (Dmean, V20). Wilcoxon signed-rank
tests were used to estimate statistical significance of dif-
ferences between FB and DIBH.
Radiation treatment using the CatalystTM/SentinelTM
system
The SentinelTM system is a laser-based (λ = 635–690 nm)
optical surface scanning system, which is used during CT
acquisition in order to create a reference surface scan in
free breathing and to record the breathing patterns includ-
ing the deep inspiration amplitude during the deep inspir-
ation manoeuvre. The gating window was initially set
arbitrarily to 4 mm at the level of stable deep-inspiration
(see example of gating window in Fig. 2). The amplitude
of the gating window should not exceed the amplitude of
free breathing. When a stable and constant breath hold
was observed during initial training, the gating window
was stepwise reduced to a maximum of 2 mm during the
training at the CT. If the gating window was adjusted too
small during initial training, some patients had problems
in keeping the inspiration level within the predefined
range. For visual feedback of the breathing position for
the patient, Cinemizer® OLED (Carl Zeiss, Oberkochen,
Germany) video goggles were used. Throughout the DIBH
CT acquisition for treatment planning, the patient was
asked to keep a maximum comfortable deep inspiration.
The patient was requested to locate (breath) the orange
indicator bar into the predefined gating window (green
box) following an audio command signal of the radiation
therapist in order to start CT acquisition or radiotherapy
treatment (see Fig. 2). CT acquisition time ranged between
10 and 15 s, depending on the length of the thorax of each
patient. In general, the pitch of the CT couch has been set
to 15 mm/s. The gaiting window was defined due to the
deep inspiration amplitude during the deep inspiration
manoeuvre, detected through the Sentinel system in the
CT room. The measurement of the sentinel system was
then transferred to the Catalyst system which is intercon-
nected to the LINAC.
The CatalystTM system works through an optical sur-
face scanning with LED lights (blue: λ = 450 nm) and
reprojection captured by a CCD camera (green: λ =
528 nm; red: λ = 624 nm), which provides target position
control during set-up and treatment (Fig. 3). For 3D sur-
face reconstruction, the system uses a non-rigid body al-
gorithm to calculate the distance between the surface
and the iso-center and using the principle of optical tri-
angulation. The system works with a frame rate of 200
frames per second. For further details regarding the Cat-
alystTM system, see: Freislederer et al. [26] or the manu-
facturer's website.
Fig. 2 Visual feedback of the breathing position for the patient: gating window (green box) and breathing position (orange bar). Following an
audio command the patient is requested to locate (breath) the orange bar into the predefined gating window. Original motion signal of a
breathing curve depicting automated beam gating
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During treatment delivery, a spot on the patient’s ster-
num, monitored by the CatalystTM optical surface scan-
ner was used to initiate treatment delivery automatically
using the Elekta ResponseTM interface. The size of the
spot on the patient's surface is a circle with the radius of
r = 20 mm. The system averages all measurement points
in that radius in order to acquire a reproducible gating
spot. The tracking of this spot is ensured by the system's
software and has been tested in advance.
For the first treatment, patient positioning and stable
deep breath-hold were verified using the SentinelTM sur-
face scan acquired during CT simulation as a reference. A
new reference scan was taken manually in the CatalystTM
system after the patient has been repositioned during the
first treatment fraction. The new reference image is neces-
sary due to the fact that during the planning CT, the
image was acquired using the Sentinel laser based-system
while the patient was lying in the CT gantry in the refer-
ence position. The new surface scan during the first treat-
ment fraction was acquired using the Catalyst system and
has a far better resolution due to the fact that the Catalyst
system works with another acquisition method, using op-
tical visible light. Furthermore, the patient's surface will be
better visible, as there is no interference with the CT-
gantry, which leads to better positioning results because of
an even better and clearer reference image. The new refer-
ence image was automatically set as the new reference
image used for the following treatment fractions. Further-
more following our clinical routine, manually triggered
iViewTM portal images (Elekta AB, Sweden) were acquired
once a week during deep inspiration breath-hold in order
to verify the patient positioning. In these images the dis-
tance from the deep field edge to the thoracic wall (central
lung distance, CLD) was measured and documented.
Results
Dual treatment planning was performed for all 13 pa-
tients. Four patients presented with a low cardiac dose
(V25 of the heart: 0 %) (Table 1), and did therefore not
receive radiotherapy in DIBH. The remaining nine pa-
tients had higher cardiac doses (Table 2) and were
treated in DIBH RT.
Training and treatment delivery using the CatalystTM/
SentinelTM system
If the patient was eligible for the study (ability of breath-
hold for 20 s) a brief training was performed during pa-
tient consultation in order to get familiar with the DIBH
manoeuvre. Thereafter, all patients received a short intro-
duction into technical details and the hardware (video
goggles), followed by a profound 15-min hands-on train-
ing immediately prior to CT acquisition. Following this
training, all 13 patients were able to complete CT simula-
tion without facing any substantial problems. The average
gating window over all patients was 3.1 mm. The mean
deep inspiration breathing amplitude measured at the
xiphoid with the SentinelTM system was 16.5 mm (range
11.9 – 24.0 mm). The nine patients successfully completed
overall 225 radiotherapy fractions with good compliance
and no interruption. Overall, the workflow operated time-
efficiently. Despite the additional time reserved for patient
training, dual CT acquisition and treatment planning, no
significant extra treatment time has been observed during
treatment delivery. The most time-consuming part ac-
counting for one or two extra minutes was the set-up of
the visual feedback, for which the patient had to position
the video goggles prior to treatment delivery. The max-
imum time of one radiation field was about 15 s (~150
Monitor Units (MUs), Dose Rate ~ 660 MUs/min). During
Fig. 3 Typical patient treatment setup: the trigger point on the sternum of the patient (red dot), the treatment beam visualized by light (green),
the room lasers (red lines), the scanning light of the catalyst (blue) and video goggles
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the gantry rotation of the LINAC in between two treat-
ment fields, all patients were able to have enough rest to
maintain a stable breath hold during the subsequent treat-
ment field. In conclusion, no substantial additional overall
treatment time has been observed.
Verification of deep inspiration breath-hold
To verify precise dose delivery in DIBH a total of 55
iViewTM portal images have been acquired over the
course of treatment. There were no major deviations re-
quiring additional imaging. The standard deviations of




Dmax (Gy) 10,94 ± 2,48 [7,81–13,31] 6,37 ± 1,63 [4,89–8,12] p = 0,068
Dmean (Gy) 1,14 ± 0,15 [1,00–1,28] 0,97 ± 0,15 [0,82–1,18] p = 0,068
V5 (%) 0,68 ± 0,36 [0,22–1,06] 0,23 ± 0,23 [0,01–0,47] p = 0,068
V10 (%) 0,05 ± 0,04 [0,00–0,10] 0,00 ± 0,01 [0,00–0,01] p = 0,109
V15 (%) 0,01 ± 0,01 [0,00–0,01] 0,00 ± 0,00 [0,00–0,00] p = 0,157
V25 (%) 0,00 ± 0,00 [0,00–0,00] 0,00 ± 0,00 [0,00–0,00] p = 1,000
LAD
Dmean (Gy) 3,45 ± 1,16 [2,19–4,97] 2,46 ± 0,66 [1,82–3,07] p = 0,068
D2% (Gy) 6,11 ± 1,91 [3,82–8,47] 4,90 ± 1,69 [3,41–6,62] p = 0,465
Ipsilateral lung
Dmean (Gy) 6,38 ± 1,66 [5,10–8,76] 6,01 ± 1,76 [4,09–8,12] p = 0,465
V20 (%) 10,81 ± 3,90 [8,14–16,44] 9,88 ± 3,87 [5,69–14,60] p = 0,273




Dmax (Gy) 47,90 ± 1,39 [45,38–50,18] 19,74 ± 15,52 [6,41–48,23] p = 0,008
Dmean (Gy) 2,73 ± 1,40 [1,44–5,81] 1,31 ± 0,15 [1,08–1,49] p = 0,011
V5 (%) 6,75 ± 4,39 [3,11–15,90] 1,18 ± 0,77 [0,17–2,55] p = 0,008
V10 (%) 4,12 ± 3,45 [1,53–11,64] 0,26 ± 0,39 [0,00–1,12] p = 0,008
V15 (%) 3,39 ± 3,18 [1,15–10,40] 0,14 ± 0,25 [0,00–0,74] p = 0,008
V20 (%) 2,92 ± 2,95 [0,92–9,48] 0,09 ± 0,18 [0,00–0,53] p = 0,008
V25 (%) 2,55 ± 2,74 [0,69–8,68] 0,06 ± 0,14 [0,00–0,42] p = 0,008
V35 (%) 1,86 ± 2,30 [0,37–7,04] 0,03 ± 0,08 [0,00–0,23] p = 0,008
V45 (%) 0,84 ± 1,40 [0,03–4,12] 0,01 ± 0,02 [0,00–0,07] p = 0,008
LAD
Dmean (Gy) 18,91 ± 9,78 [4,82–33,26] 4,19 ± 1,52 [2,53–6,83] p = 0,008
D2% (Gy) 38,55 ± 12,40 [9,02–48,71] 9,66 ± 6,30 [3,64–22,12] p = 0,008
D2% 10 mm expanded (Gy) 48,63 ± 1,54 [44,97–50,60] 29,98 ± 15,52 [6,85–47,41] p = 0,008
Ipsilateral lung
Dmean (Gy) 8,01 ± 2,02 [5,50–11,43] 6,45 ± 1,31 [5,06–7,98] p = 0,008
V20 (%) 14,87 ± 4,41 [9,06–22,03] 10,96 ± 3,10 [6,87–47,41] p = 0,008
Contralateral lung
Dmean (Gy) 0,48 ± 0,17 [0,32–0,76] 0,51 ± 0,13 [0,32–0,67] p = 0,953
PTV
V95 (%) 81,78 ± 2,92 [77,32–85,95] 81,04 ± 4,95 [68,81–85,13] p = 0,953
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the CLD were varying between 0.12 and 0.29 cm. The
mean value of the standard deviations over all patients
was 0.16 cm, which is an acceptable value for clinical
routine.
Doses exposure of the heart and LAD
Mean PTV volumes were 1065 ccm for FB and 1059 ccm
for DIBH (p = 0.859). Regarding patients treated in DIBH
(Table 2), the mean heart dose was 2.73 Gy (range: 1.44–
5.81 Gy) in FB as compared to 1.31 Gy (range: 1.09–
1.49 Gy) in DIBH. Overall, the mean heart dose could be
decreased by 52 % in patients treated in DIBH (p = 0.011).
The mean dose to the LAD artery was 18.91 Gy (4.82–
33.26 Gy) in FB versus 4.19 Gy (2.53–6.83 Gy) in DIBH,
respectively. That corresponds to a significant mean dose
reduction of 78 % (p = 0.008). V25 of the whole heart was
2.55 % (0.69 – 8.68 %) in FB as compared to 0.06 % (0.00–
0.14 %) in DIBH. In six patients the V25 could be reduced
to 0 % using DIBH.
Concerning maximal dose exposure to the heart in FB,
the maximum heart dose was 47.90 Gy (45.38–50.18 Gy)
and the dose to 2 % of the volume of the LAD, was
38.55 Gy (9.02–48.71 Gy). Through the use of the DIBH
manoeuvre the maximum dose to the heart could be re-
duced to 19.74 Gy (6.41–48.23 Gy) and the D2% of the
LAD was reduced to 9.66 Gy (3.64–22.12 Gy) in DIBH.
This corresponds to a highly significant dose reduction
of 59 % (p = 0.008) for the maximum heart dose and
75 % (p = 0.008) for the D2% of the LAD.
Dose exposure of the lung
Since DIBH strongly affects the anatomy of the surround-
ing lung, potential changes of the dose exposure to the
ipsi- and contralateral lung were analysed. The mean dose
to the left lung could be decreased in all patients, while
the dose to the right lung was not significantly changed
(p = 0.953) with a Dmean of the right lung in DIBH of
0.51 Gy (0.32–0.67 Gy). Concerning the left lung, a mean
dose of 8.01 Gy (5.50–11.43 Gy) was detected in FB and
6.45 Gy (5.06–7.98 Gy) in DIBH, which corresponds to a
significant absolute reduction of 1.56 Gy (p = 0.008). Re-
garding the dose distribution of the left lung volume re-
ceiving more than 20 Gy (V20), the V20 could be decreased
by 26 % (14.87 to 10.96 %, p = 0.008).
Collapsed cone vs. pencil beam
As commonly known in medical physics, dose calcula-
tions are heavily influenced by the used algorithms.
Therefore, we performed dose calculations using two
different algorithms (CCC and PBC) and compared dose
distributions. As shown in Fig. 4 there are certain dosi-
metric differences concerning PBC. Mean V95% of the
PTV for FB was 81.78 / 87.25 % (CCC / PBC) versus
80.82 / 87.46 % for DIBH. V20 of ipsilateral lung was
14.87 / 14.25 % for FB and 10.96 / 10.13 % for DIBH.
Maximum heart dose in FB was 47.90 / 48.53 Gy as
compared to 19.74 / 18.87 Gy in DIBH. All differ-
ences were significant (heart max (DIBH): p = 0.038;
others: p = 0.008).
Discussion
DIBH is suggested to be a robust method to reduce the
radiation dose to the heart. The present data show that
using the DIBH technique during RT could significantly
reduce high dose areas and mean doses to the heart.
This may be of particular clinical value for long-term
breast cancer survivors in order to reduce the risk of late
cardiac morbidity and mortality [27].
In the present study, DIBH resulted in a reduction of
the mean heart radiation dose of absolute 52 % (2.73 to
1.31 Gy). Similarly, Hjelstuen et al. [18], Vikström et al.
[28] and Stranzl et al. [17] found mean cardiac dose re-
ductions between 50 and 56 % through the application of
DIBH as compared to conventional RT. The latest study
by Darby et al. [29] showed that rates of major coronary
events increased linearly with the mean dose to the heart
by 7.4 % per Gy. Using these risk models [29], the rate of
major coronary events could theoretically be decreased by
roughly 10 % through the use of DIBH.
Although the effect of DIBH in reducing the mean
heart dose is consistent with other studies, the present
planning study shows even better simulated results re-
garding decreased dose exposure to the LAD. In the
present study, dose reduction of the LAD by application
of the DIBH manoeuvre showed significantly decreased
mean and D2% doses to the LAD of absolute 78 and
75 %, respectably. In contrast, the studies of Hjelstuen
[18] and Vikström [28] documented a mean LAD dose
reduction of 56–65 % and a maximum dose reduction
by 39 (D2%) to 57 % (Dmax). Obviously, there are certain
limitations of this way of comparing and evaluating radi-
ation doses of organs at risk from different studies. Be-
sides the different definitions of “maximum dose” (D2%
versus Dmax), there might be a heterogeneity caused by
the different organ at risk delineations of the heart.
While some studies delineated the entire heart [30] as
organ at risk, others limited the contours to the left ven-
tricle [31, 32], the pericardium [32], or the LAD alone
[33, 34]. To minimize the bias in the present planning
study, the heart and LAD were delineated in accordance
with the CT-based heart atlas developed by Feng et al.
[24]. Furthermore, the algorithm used for dose calcula-
tion can significantly influence final dose distribution
and the magnitude of dose reduction to the heart. To
compare the different dose distributions in the present
planning study, all plans were calculated using both al-
gorithms, PBC and CCC. As one would expect, the
mean V95% of the PTV and the mean and maximum
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heart doses showed divergent simulated results depend-
ing on the applied algorithm. As pointed out by Koeck
et al. [35], PBC is known to underestimate low dose
areas, whereas high dose areas are overestimated [36].
This fact might further be influenced by the individual
delineation of the target volume. The delineation of the
PTV up to the skin surface may account for variations
and inaccuracies in the expected external beam surface
dose calculations and influence PTV coverage. Taken to-
gether, the comparison of dose distributions from differ-
ent studies should be interpreted with caution.
The present study delivered DIBH RT using the Cata-
lystTM/SentinelTM system (C-RAD AB, Uppsala, Sweden).
While the CatalystTM system provided the target position
control during set-up and treatment through the optical
surface scanning, the SentinelTM system recorded the
deep inspiration amplitude through a laser based optical
surface scanning system. An active patient feedback sys-
tem (audio-visual guidance) was used to reach the optimal
breathing position. The individually chosen gating window
of 2–4 mm proved to be practicable in clinical routine
and is within the range of previous studies [17, 18, 37]. If
the gating window was adjusted too small during initial
training, some patients had problems in keeping the in-
spiration level within the predefined range. With longer
training, an individual reduction of the gating window
seems feasible and should be evaluated in further studies.
The present study assessed the practicality and feasibil-
ity for radiotherapy in DIBH by means of CatalystTM/Sen-
tinelTM system in clinical practice. The workflow operates
time-efficiently and reliably, leading to good patient com-
pliance. In clinical routine, most patients were treated in
15–20 min time slots, depending on the number of radi-
ation fields. Verification of the DIBH with iViewTM portal
images has shown excellent results with a reproducible
breath hold level. The mean value of the standard devia-
tions of the CLD over all patients was 0.16 cm. However,
for a more conclusive and elaborated verification of exter-
nal surface position reproducibility (e.g. 3D localizations
of patient rib cage compared with the surface information)
additional investigations are needed.
Compared to the Active Breathing Control (ABC) de-
vice, the CatalystTM/SentinelTM system is more comfort-
able and less invasive, even though the reproducibility is
limited due to irradiation within a 2-4 mm range (gating
window) and the theoretical possibility of breathing dur-
ing irradiation. Other limitations of an optical system
are problems in detecting the surface of the object, e.g.
in regions with increased body hair, which is obviously
negligible in treatment of female breast cancer patients.
Furthermore, in obese patients the vision of the Senti-
nelTM system in the CT room could be limited due to a
prominent belly.
Unfortunately, we could not define a valid criterion to
select patients who benefit from DIBH in terms of mean
heart dose, before initiation of RT. Despite individual
anatomic characteristics, in our patients a suitable par-
ameter seems to be the V25 of the heart resulting from
treatment planning in FB. In the present study, the V25
of the heart has been used as a cut-off value in order to
decide if a patient was treated using the DIBH
manoeuvre or not. A V25 of 0 % was an indicator for low
cardiac dose exposure and for whether the heart was
within the treatment fields or not.
The present study was very useful in providing an
insight into an alternative gating modality using the Cat-
alystTM/SentinelTM surface scanning system for DIBH.
Concerning the clinical outcome and long-term benefit,
it seems unlikely to make a general prevision of the
magnitude of benefit regarding late cardiac toxicity for
patients treated in DIBH. This correlation might be
strongly influenced by a variety of factors, other than the
solely effect of radiotherapy. On the one hand, additional
systemic therapies (e.g. anthracycline, trastuzumab) may
Fig. 4 Mean PTV V95%, heart mean and maximum dose comparison between pencil beam and collapsed cone for FB and DIBH of nine patients
treated in DIBH
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synergistically influence the incidence of cardiovascular
disease (CVD), and on the other hand, CVD taken by it-
self is strongly influenced by cardiovascular risk factors.
Conventional and influenceable risk factors are hyper-
tension, hypercholesterolemia, increased body mass
index, diabetes mellitus and smoking [38]. Therefore,
additional primary and secondary prevention and risk
reduction therapy for patients undergoing radiotherapy
and presenting with risk factors for coronary and other
atherosclerotic vascular disease could be beneficial for
overall outcome [27]. In order to predict the individual
treatment benefit from DIBH, further studies are needed
with longer follow-up and better patient stratification. In
this context, the use of screening strategies could help
identifying patients that are more likely to benefit from
DIBH RT [39]. Due to the above-mentioned limitations
and in absence of long-term follow-up, to date, we
cannot extrapolate possible clinical benefits from the
present study. However, taking into account the results
of Darby et al. [29], we can hypothesize a significant
clinical benefit for patients treated with DIBH due to the
significant reduction of radiation exposure of the heart.
Conclusion
The CatalystTM/SentinelTM system (C-RAD) enabled a
fast and reliable application and surveillance of DIBH in
daily clinical routine. Furthermore, the present data
show that using the DIBH technique during RT could
significantly reduce high dose areas and mean doses to
the heart in patients with left-sided breast cancer.
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